Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study

Affiliations

• ¹ Department of Hematology, Hôpital Haut-Lévêque, University Hospital Bordeaux, Pessac. [email protected].
• ² Hematology, University Hospital Ghent, Ghent.
• ³ Service d'Hématologie Clinique, University Hospital Hôtel-Dieu, Nantes.
• ⁴ Service d'Hématologie Clinique, /IUC Oncopole, Toulouse.
• ⁵ Hémopathies Lymphoïdes, Hôpital Henri Mondor, Creteil.
• ⁶ CHU de Tours, Hôpital de Bretonneau, Tours.
• ⁷ CHU Dijon, Hôpital Du Bocage, Dijon.
• ⁸ University of Lille, CHU Lille, Service des Maladies du Sang, Lille.
• ⁹ Sorbonne Université, INSERM, UMR_S 938, Centre de Recherche Saint-Antoine, Team Proliferation and Differentiation of Stem Cells, Assistance Publique-Hôpitaux de Paris, Hôpital Pitié Salpetrière, Département d'Hématologie, Paris.
• ¹⁰ Institut Curie Paris, Paris.
• ¹¹ Institut Paoli-Calmettes, Marseille.
• ¹² CHU de Reims,Hôpital Robert Debré, Reims.
• ¹³ CHD Vendée, La Roche-sur-Yon.
• ¹⁴ Zuyderland MC, Sittard.
• ¹⁵ Northwest Clinics, Alkmaar.
• ¹⁶ Biostatistical Department, Hôpital Saint Louis, Paris.
• ¹⁷ Janssen Research and Development, LLC, Raritan, NJ.
• ¹⁸ Janssen Research and Development, Beerse.
• ¹⁹ Janssen Research and Development, LLC, Leiden.
• ²⁰ Erasmus University Medical Center Cancer Institute, Rotterdam.
• ²¹ Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Amsterdam.